Texas Patent of the Month – May 2024
Nexalin Technology, Inc. has been granted a patent for their new approach to treating anxiety, depression, and insomnia through transcranial alternating current stimulation (tACS). This innovative approach targets the frontal cortex with a precisely modulated alternating current designed to evoke specific metabolic responses in the brain’s neurons. By using a carrier waveform with a carefully balanced duty cycle and current amplitude, Nexalin’s method ensures that each pulse of stimulation is consistent and effective.
The treatment involves generating a carrier waveform, which is an alternating current, and modulating it to produce a stimulation current. This current creates a stimulation envelope with pulses at two distinct frequencies: a stable first frequency and a varying second frequency. The dual-frequency stimulation is tailored to optimize neural entrainment, reducing patient discomfort compared to earlier direct current (DC) methods.
Traditional electrostimulation techniques often cause discomfort due to the presence of a DC component, which can lead to skin irritation and pain. Nexalin’s approach mitigates these issues by maintaining a charge-balanced alternating current, preventing the unpleasant side effects associated with DC rectification in the skin. This allows for a higher power delivery without discomfort, enhancing the treatment’s efficacy.
The therapy sessions are typically about an hour long, divided into three 20-minute segments with varying second frequencies. This dynamic frequency adjustment helps in maximizing the therapeutic impact on the patient’s brain. Additionally, the system includes real-time feedback mechanisms to adjust the stimulation parameters based on electrode contact impedance, ensuring optimal delivery and effectiveness.
Nexalin Technology’s method represents a significant advancement in electrostimulation therapy, offering a more comfortable and effective treatment for patients suffering from anxiety, depression, and insomnia. By refining the delivery of electrical stimulation, this technology opens new avenues for non-invasive mental health treatments.
Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.
Who We Are:
Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.
Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.